[關(guān)鍵詞]
[摘要]
目的 分析泰達國際心血管病醫(yī)院心血管疾病患者發(fā)生血流感染的病原菌分布及耐藥特征,為臨床合理應(yīng)用抗菌藥物提供依據(jù)。方法 對2012年1月—2020年12月泰達國際心血管病醫(yī)院血流感染病原菌的分布及耐藥性進行回顧性分析。結(jié)果 共檢出病原菌234株,其中革蘭陰性菌133株,構(gòu)成比為56.8%,主要為大腸埃希菌、肺炎克雷伯菌和陰溝腸桿菌;革蘭陽性菌95株,構(gòu)成比為40.6%,主要為凝固酶陰性葡萄球菌、草綠色鏈球菌和金黃色葡萄球菌;真菌6株,構(gòu)成比為2.6%。大腸埃希菌、肺炎克雷伯菌和陰溝腸桿菌對碳青霉烯類和阿米卡星保持高度敏感。葡萄球菌屬中,凝固酶陰性葡萄球菌中甲氧西林耐藥菌株檢出率顯著高于金黃色葡萄球菌。未發(fā)現(xiàn)耐利奈唑胺、萬古霉素和替考拉寧革蘭陽性菌。結(jié)論 泰達國際心血管病醫(yī)院心血管疾病患者血流感染的病原菌主要以革蘭陰性菌為主,應(yīng)加強血流感染病原菌的耐藥性監(jiān)測,為臨床醫(yī)生經(jīng)驗用藥提供依據(jù)。
[Key word]
[Abstract]
Objective To investigate the distribution and drug resistance of bloodstream infection pathogens in cardiovascular patients in TEDA International Cardiovascular Hospital, and to provide evidence for rational use of antibiotics.Methods The distribution and drug resistance of bloodstream infection pathogens in TEDA International Cardiovascular Hospital were retrospectively analyzed from January 2012 to December 2020.Results Total 234 strains of bloodstream infection pathogens were isolated. Gram-negative bacteria (133 strains) accounted for 56.8%, and main of them were Escherichia coli, Klebsiella pneumonia, and Enterobacter cloacae. Gram-positive bacteria were 95 strains (40.6%), and main of them were coagulase negative Staphylococcus, Viridans streptococcus, and Staphylococcus aureus. Fungi were 6 strains, accounting for 2.6%. Escherichia coli, Klebsiella pneumonia, and Enterobacter cloacae were highly sensitive to carbapenems and amikacin. Among Staphylococcus, the detection rate of methicillin resistant coagulase negative Staphylococcus was higher than that of Staphylococcus aureus. No Gram-positive bacteria was resistant to linezolid, vancomycin, and teicopalnin.Conclusions Gram-negative bacteria are the main pathogens of bloodstream infection in cardiovascular patients in TEDA International Cardiovascular Hospital. It is necessary to strengthen surveillance of drug resistance of pathogens in bloodstream infection, in order to provide evidence for clinical doctors to use drugs empirically.
[中圖分類號]
R978.1
[基金項目]